Evoke Pharma is a single-product specialty pharmaceutical company focused on gastrointestinal disorders. Its sole product is Gimoti (metoclopramide) nasal spray, the only FDA-approved nasally-administered treatment for diabetic gastroparesis — a chronic condition in which the stomach empties too slowly, causing nausea, vomiting, and abdominal pain. The core clinical argument for Gimoti is delivery: because gastroparesis disrupts stomach motility, oral medications are absorbed unpredictably, whereas Gimoti delivers metoclopramide through the nasal mucosa directly into the bloodstream, bypassing the digestive tract entirely. Evoke sells Gimoti in the U.S. exclusively through its commercial partner, Eversana, which provides a dedicated sales force targeting gastroenterologists, internists, and primary care physicians. Prescription fulfillment runs through ASPN Pharmacy, a specialty pharmacy network that manages prior authorizations and insurance reimbursement. Evoke retains more than 80% of net product profits after reimbursing Eversana's commercialization costs, though the company carries a large deferred cost balance and has been loss-making since inception, funding operations primarily through equity raises. Revenue is driven by prescriber growth, prescription fill rates, and payer coverage. Evoke's growth strategy focuses on expanding its prescriber base — currently around 2,553 cumulative prescribers — while improving fulfillment rates through better prior authorization completion and pharmacy network coverage. An emerging opportunity is the overlap with GLP-1 drug users, who show elevated rates of gastroparesis-like symptoms.